Ask AI

From Evidence to Action: Expert Strategies for Individualizing CD38-Based Quadruplet Therapy in Transplant-Eligible NDMM

Gain expert insights into anti-CD38–based quadruplet regimens for transplant-eligible newly diagnosed multiple myeloma to individualize treatments and support equitable access through an expert-authored ClinicalThought commentary and certified on-demand webcast with accompanying downloadable slides.

Share

Program Content

Activities

NDMM CD38 Quadruplet Therapy
From Evidence to Action: Expert Strategies for Individualizing CD38-Based Quadruplet Therapy in Transplant-Eligible NDMM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 20, 2026

Activities

CD38 Quadruplets in Transplant Eligible NDMM
From Evidence to Action: Expert Strategies for Individualizing CD38-Based Quadruplet Therapy in Transplant-Eligible NDMM
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 18, 2026

Expires: November 17, 2026

Activities

CD38 Quadruplets for TE NDMM
FAQs: Individualizing Anti-CD38–Based Quadruplet Therapy in Transplant-Eligible NDMM
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 19, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme